EUVIMEDEUVIMED entdecken
Open Access

Urinary Catecholamines Predict Relapse During Complete Remission in High-Risk Neuroblastoma

Yvette A H Matser iD, Atia Samim iD, Marta Fiocco iD, Marieke van de Mheen, Maria van der Ham, Monique G M de Sain-van der Velden iD, Nanda M Verhoeven-Duif, Martine van Grotel, Kathelijne C J M Kraal, Miranda P Dierselhuis, Natasha K A van Eijkelenburg iD, Karin P S Langenberg iD und 3 weitere

JCO Precision Oncology · 2025-01 · (9)

DOI: 10.1200/po-24-00491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-01. Verfasst von Yvette A H Matser und 14 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Neuroblastoma, Catecholamines, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Urinary catecholamine metabolites are well-known biomarkers for the diagnosis (Dx) of neuroblastoma, but their clinical significance in determining therapy response during treatment is not well established. Therefore, catecholamines are not included in criteria for assessing response and complete remission (CR). This study investigated the use of urinary catecholamines in response monitoring and predicting survival outcomes. METHODS From 2005 to 2021, a panel of eight urinary catecholamines were measured in patients with high-risk neuroblastoma at Dx and at standard evaluation moments during treatment. At the same time points, response and CR were assessed according to the revised International Neuroblastoma Response Criteria. RESULTS The total cohort consists of 153 high-risk patients, and at least one of the eight metabolites was elevated (ie, catecholamine status positive) in 141 of 146 (97%), 104 of 128 (81%), and 39 of 69 (57%) patients at Dx, postinduction, and at CR, respectively. Primary tumor resection significantly reduced catecholamine levels ( P < .01). A positive catecholamine status at Dx, during treatment, and at the end of treatment was not significantly associated with event-free survival (EFS) or overall survival (OS). However, in patients who achieved CR, those with a positive catecholamine status had poor EFS (38% v 80%, respectively; P < .01) and OS (52% v 86%, respectively; P = .01) compared with those with a negative catecholamine status. Notably, 3-methoxytyramine levels at CR seem to be a prognostic marker for poor OS (hazard ratio, 7.5 [95% CI, 2.0 to 28.6]). CONCLUSION Catecholamine measurements contribute to the assessment of CR and identifies patients with high-risk neuroblastoma with an increased risk of relapse and death.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaCatecholaminesNeoplasm Recurrence, LocalHumansMaleFemaleChild, PreschoolInfantChildRemission InductionBiomarkers, TumorAdolescentPrognosis

Substanzen

CatecholaminesBiomarkers, Tumor

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Division of Imaging and Oncology, University Medical Center, Utrecht, the Netherlands.
  • Department of Biomedical Data Science, Section Medical Statistics, Leiden University Medical Centre, Leiden, the Netherlands.
  • Mathematical Institute, Leiden University, Leiden, the Netherlands.
  • Department of Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, Utrecht, the Netherlands.
  • Laboratory Genetic Metabolic Diseases, Amsterdam UMC, Free University Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Yvette A H Matser, Atia Samim, Marta Fiocco, Monique G M de Sain-van der Velden, Natasha K A van Eijkelenburg, Karin P S Langenberg, Max M van Noesel, André B P van Kuilenburg, Godelieve A M Tytgat

Zitieren

APA

Matser, Y. A. H., Samim, A., Fiocco, M., van de Mheen, M., van der Ham, M., de Sain-van der Velden, M. G. M., Verhoeven-Duif, N. M., van Grotel, M., Kraal, K. C. J. M., Dierselhuis, M. P., van Eijkelenburg, N. K. A., Langenberg, K. P. S., van Noesel, M. M., van Kuilenburg, A. B. P., & Tytgat, G. A. M. (2025). Urinary Catecholamines Predict Relapse During Complete Remission in High-Risk Neuroblastoma. JCO Precision Oncology. https://doi.org/10.1200/po-24-00491

Vancouver

Matser YAH, Samim A, Fiocco M, van de Mheen M, van der Ham M, de Sain-van der Velden MGM, et al. Urinary Catecholamines Predict Relapse During Complete Remission in High-Risk Neuroblastoma. JCO Precision Oncology. 2025. doi:10.1200/po-24-00491

BibTeX
@article{Matser2025,
  author = {Matser, Yvette A H and Samim, Atia and Fiocco, Marta and van de Mheen, Marieke and van der Ham, Maria and de Sain-van der Velden, Monique G M and Verhoeven-Duif, Nanda M and van Grotel, Martine and Kraal, Kathelijne C J M and Dierselhuis, Miranda P and van Eijkelenburg, Natasha K A and Langenberg, Karin P S and van Noesel, Max M and van Kuilenburg, André B P and Tytgat, Godelieve A M},
  title = {Urinary Catecholamines Predict Relapse During Complete Remission in High-Risk Neuroblastoma},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-24-00491}
}
Kostenlos starten →